{
    "nct_id": "NCT05605522",
    "official_title": "A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours",
    "inclusion_criteria": "* Signed ICF prior to initiation of any study-specific procedures\n* Histologically and/or cytologically confirmed solid tumor that is metastatic or locally advanced, inoperable, or recurrent. Solid tumors indications may include PDAC, CRC, NED prostate cancer, gastric cancer, SCCHN, and Ewing sarcoma.\n* Disease that has progressed despite prior treatment, and for which additional effective standard therapy is not available or is contraindicated, not tolerable, or the patient refuses standard therapy\n* Measurable disease per RECIST v.1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Sufficient target expression in at least one measurable lesion as determined by imaging following injection of [111In]-FPI-2058\n* Adequate organ function\n* Tumor tissue (either archival within the last 24 months or fresh biopsy)\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with any radiopharmaceutical\n* Contraindications to or inability to perform the imaging procedures required in this study\n* Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents within certain amount of time prior to administration of the first dose of [111In]-FPI-2058\n* Radiation therapy (RT) within 28 days prior to the first dose of [111In]-FPI-2058\n* Patients with known CNS metastatic disease\n* Concurrent severe and/or uncontrolled illness that would limit compliance with study requirements\n* Known or suspected allergies or contraindication to the investigational treatment\n* Received any type of vaccine within 30 days prior to the first dose of [111In]-FPI-2058",
    "miscellaneous_criteria": "Key"
}